• +1-646-491-9876
    • +91-20-67278686

    Search

    5' Nucleotidase Pipeline Review H2 2017

    5' Nucleotidase Pipeline Review H2 2017

    • Report Code ID: RW0001884167
    • Category Pharmaceuticals
    • No. of Pages 36
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2017

    Summary

    According to the recently published report '5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2017'; 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.

    The report '5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2017' outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Metastatic Colorectal Cancer, Ovarian Cancer and Solid Tumor.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
    - The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
    - The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
    Bristol-Myers Squibb Company
    Corvus Pharmaceuticals Inc
    Innate Pharma SA
    MedImmune LLC
    Surface Oncology Inc
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
    A-000830 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody to Inhibit CD73 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986179 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPX-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    durvalumab + oleclumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPH-53 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    oleclumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PBF-1509 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CD73 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
    5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
    Featured News & Press Releases
    Dec 19, 2016: Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway
    Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program
    Feb 24, 2014: CD73 Research Could Lead to Cancer Drug
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indication, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products under Investigation by Universities/Institutes, H2 2017
    Products under Investigation by Universities/Institutes, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pipeline by Bristol-Myers Squibb Company, H2 2017
    Pipeline by Corvus Pharmaceuticals Inc, H2 2017
    Pipeline by Innate Pharma SA, H2 2017
    Pipeline by MedImmune LLC, H2 2017
    Pipeline by Surface Oncology Inc, H2 2017
    Dormant Projects, H2 2017

    List of Figures

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Top 10 Indications, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Bristol-Myers Squibb Company
    Corvus Pharmaceuticals Inc
    Innate Pharma SA
    MedImmune LLC
    Surface Oncology Inc

    Request for Sample

    Report Url http://www.reportsweb.com//5-nucleotidase-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//5-nucleotidase-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//5-nucleotidase-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments